Log in

Celldex Therapeutics Stock Forecast, Price & News

+0.83 (+6.85 %)
(As of 09/18/2020 09:20 PM ET)
Today's Range
Now: $12.94
50-Day Range
MA: $11.22
52-Week Range
Now: $12.94
Volume1.32 million shs
Average Volume1.26 million shs
Market Capitalization$506.29 million
P/E RatioN/A
Dividend YieldN/A
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Read More
Celldex Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:CLDX



Sales & Book Value

Annual Sales$3.57 million
Book Value$5.83 per share


Net Income$-50,880,000.00
Net Margins-1,035.16%


Market Cap$506.29 million
Next Earnings Date11/10/2020 (Estimated)
+0.83 (+6.85 %)
(As of 09/18/2020 09:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLDX News and Ratings via Email

Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

How has Celldex Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLDX shares have increased by 537.4% and is now trading at $12.94.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Celldex Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Celldex Therapeutics

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Celldex Therapeutics

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.77) by $0.20. The biopharmaceutical company earned $0.24 million during the quarter, compared to analysts' expectations of $0.90 million. Celldex Therapeutics had a negative return on equity of 36.44% and a negative net margin of 1,035.16%.
View Celldex Therapeutics' earnings history

When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?

Shares of Celldex Therapeutics reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLDX?

2 brokers have issued 12 month price targets for Celldex Therapeutics' shares. Their forecasts range from $16.00 to $18.00. On average, they expect Celldex Therapeutics' stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 31.4% from the stock's current price.
View analysts' price targets for Celldex Therapeutics

Are investors shorting Celldex Therapeutics?

Celldex Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,430,000 shares, an increase of 102.5% from the August 15th total of 1,200,000 shares. Based on an average daily volume of 2,760,000 shares, the short-interest ratio is currently 0.9 days.
View Celldex Therapeutics' Short Interest

Who are some of Celldex Therapeutics' key competitors?

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include Opko Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Precigen (PGEN), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and Novavax (NVAX).

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the following people:
  • Anthony S. Marucci, President, Chief Executive Officer & Director
  • Sam Martin, CFO, Secretary, Treasurer & Senior Vice President
  • Tibor Keler, Chief Scientific Officer & Executive VP
  • Elizabeth Crowley, Chief Product Development Officer & Senior VP
  • Ronald A. Pepin, Chief Business Officer & Senior Vice President

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (12.15%), RTW Investments LP (11.57%), Logos Global Management LP (8.87%), Opaleye Management Inc. (4.75%), Orbimed Advisors LLC (2.77%) and Corriente Advisors LLC (2.04%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin and Tibor Keler.
View institutional ownership trends for Celldex Therapeutics

Which institutional investors are selling Celldex Therapeutics stock?

CLDX stock was sold by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Celldex Therapeutics

Which institutional investors are buying Celldex Therapeutics stock?

CLDX stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, RTW Investments LP, Logos Global Management LP, Opaleye Management Inc., Orbimed Advisors LLC, Corriente Advisors LLC, Monashee Investment Management LLC, and Driehaus Capital Management LLC. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler.
View insider buying and selling activity for Celldex Therapeutics

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $12.94.

How big of a company is Celldex Therapeutics?

Celldex Therapeutics has a market capitalization of $506.29 million and generates $3.57 million in revenue each year. The biopharmaceutical company earns $-50,880,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe.

What is Celldex Therapeutics' official website?

The official website for Celldex Therapeutics is www.celldex.com.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.